Wright Medical Group, Inc. Reaffirms FY 2012 Guidance

Wright Medical Group, Inc. announced that it continues to anticipate fiscal 2012 net sales to be in the range of $472 million to $489 million and as-adjusted earnings per share excluding stock-based compensation to be in the range of $0.26 to $0.36 per diluted share. The Company's earnings target excludes non-compete and transition costs associated with converting a major portion of independent foot and ankle territories to direct, costs associated with the previously announced cost restructuring, possible future acquisitions, other material future business developments, non-cash stock-based compensation expense, and costs associated with the Company's DPA (including the associated independent monitor). As noted above, the Company's earnings target excludes the impact of non-cash stock-based compensation charges. While the amount of the non-cash stock-based compensation charges will vary depending upon a number of factors, the Company currently estimates that the after-tax impact of those expenses will be approximately $0.18 per diluted share for fiscal 2012. Therefore, the Company continues to anticipate fiscal 2012 as-adjusted EPS including stock-based compensation to be in the range of $0.08 to $0.18 per diluted share. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $482 million and for EPS of $0.16 for fiscal 2012.